Get the Stockscreener App
58.35
0.19%
-0.11
Pre-market:
57.95
-0.40
-0.69%
Ani Pharmaceuticals Inc stock is traded at $58.35, with a volume of 149.39K.
It is down -0.19% in the last 24 hours and up +9.37% over the past month.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
See More
Previous Close:
$58.46
Open:
$58.88
24h Volume:
149.39K
Relative Volume:
0.62
Market Cap:
$1.22B
Revenue:
$486.82M
Net Income/Loss:
$18.78M
P/E Ratio:
71.16
EPS:
0.82
Net Cash Flow:
$100.45M
1W Performance:
+7.74%
1M Performance:
+9.37%
6M Performance:
-6.17%
1Y Performance:
+5.31%
1-Day Range:
$57.98
$59.26
1-Week Range:
$54.75
$59.26
52-Week Range:
$52.50
$70.81
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(218) 634-3500
Address
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
58.35 | 1.22B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Initiated | Leerink Partners | Outperform |
| Oct-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-15-24 | Initiated | CapitalOne | Overweight |
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
Millennium Management LLC's Strategic Acquisition in ANI Pharmac - GuruFocus.com
ANI Maintains Course With Rare Disease Push In 2025 - News & Insights
Wedge Capital Management L L P NC Reduces Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal - MSN
Short Interest in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Declines By 8.5% - MarketBeat
Assenagon Asset Management S.A. Raises Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) delivers shareholders respectable 12% CAGR over 3 years, surging 6.2% in the last week alone - Simply Wall St
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now? - Yahoo Finance
Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 400 Shares of Stock - MarketBeat
Ani Pharmaceuticals senior VP sells $21,568 in stock By Investing.com - Investing.com Nigeria
Ani Pharmaceuticals senior VP sells $21,568 in stock - Investing.com
ANI Pharmaceuticals (NASDAQ:ANIP) Reaches New 52-Week LowHere's What Happened - MarketBeat
Alcami Announces CEO Transition - Quantisnow
ANI Pharmaceuticals Projects Strong Growth for 2025 - TipRanks
ANI Pharmaceuticals, Inc. Affirms Earnings Guidance for the Year 2024 and Provides Earnings Guidance for the Full Year 2025 - Marketscreener.com
ANI Pharmaceuticals Projects Strong 25% Growth for 2025, Exceeds 2024 Guidance Targets - StockTitan
ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook - GlobeNewswire
ANI Continues To Spearhead FDA’s CGT Path With Prucalopride Launch - Citeline
JPMorgan Chase & Co. Raises Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day Cgt Exclusivity - Marketscreener.com
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity - The Manila Times
ANI Pharmaceuticals Launches First Generic Motegrity with Exclusive 180-Day Market Access - StockTitan
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Short Interest in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Rises By 27.7% - Defense World
ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
ANI Pharmaceuticals CEO to Present Strategic Vision at J.P. Morgan Healthcare Conference 2025 - StockTitan
Geode Capital Management LLC Grows Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $77.71 Consensus Target Price from Analysts - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Position Reduced by Wellington Management Group LLP - MarketBeat
State Street Corp Increases Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Ani Pharmaceuticals CFO sells $418,425 in stock By Investing.com - Investing.com Nigeria
Insider Sell: Stephen Carey Sells 7,500 Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus.com
Stephen P. Carey Sells 7,500 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock - MarketBeat
Ani Pharmaceuticals CFO sells $418,425 in stock - Investing.com
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? - Yahoo Finance
ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Prospects Need A Boost To Lift Shares - Simply Wall St
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Bought by Barclays PLC - MarketBeat
Ani Pharmaceuticals Sr. VP Meredith Cook sells $14,060 in stock - Investing.com
Ani Pharmaceuticals Sr. VP Meredith Cook sells $14,060 in stock By Investing.com - Investing.com Australia
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.03 Million Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Key Pharmaceutical Suspension Market Trend 2024-2033: ANI Pharmaceuticals Launches Kionex Suspension - EIN News
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Significant Decrease in Short Interest - MarketBeat
Insider Sell: Krista Davis Sells 1,000 Shares of ANI Pharmaceuti - GuruFocus.com
ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded to "Strong-Buy" at Leerink Partnrs - MarketBeat
Leerink Partners Initiates Coverage of ANI Pharmaceuticals (ANIP) with Outperform Recommendation - MSN
ANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Analysts at Leerink Partners - MarketBeat
Where ANI Pharmaceuticals Stands With Analysts - Benzinga
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):